OBJECTIVE: To determine whether hypercholesterolaemia treatment with pravastatin causes modifications in plasma fibrinogen. DESIGN: Descriptive, prospective pharmacological intervention study, with two transversal cuts, one at the start and one after 6 months pravastatin treatment. SETTING: Health area located in the suburbs of Valencia. PATIENTS: Hypercholesterolaemia cases diagnosed de novo and treated with pravastatin for 6 months. Sample size was calculated for paired data with an alpha error of 0.05 and a beta error of 20%. The fibrinogen difference thought relevant was set at 40 mg/dl. Variability was deduced from a mini-sample of 15 cases, obtaining a total of 57 patients. Sex, age, height, weight, BMI, count, formula, globular sedimentation rate (GSR), glucaemia, total, HDL and LDL cholesterol, and triglycerides were recorded. MEASUREMENTS AND MAIN RESULTS: Mean age was 55.9, height 161.9 cm and initial weight 73.9 kg (mean BMI 28.1 kg/m(2)). After six months pravastatin treatment (10/20 mg/day) we found no significant differences in glucaemia, GSR or leukocytes. There were differences in weight, that fell by 1.5 kg (0.6 kg/m(2)), systolic pressure (4.3 mmHg) and diastolic pressure (2.7 mmHg) on average. We found the following differences for lipids: 42.3 mg/dl (15.2%) drop in mean total cholesterol, 27 mg/dl (14.5%) in LDL cholesterol, and 36.2 mg/dl (21.9%) in triglycerides. We found a mean increase in HDL cholesterol of 4.4 mg/dl. There was a mean drop of 43.7 mg/dl (11.9%) in fibrinogen. CONCLUSIONS: We found an 11.9% drop of plasma fibrinogen in patients with hypercholesterolaemia treated with pravastatin.
OBJECTIVE: To determine whether hypercholesterolaemia treatment with pravastatin causes modifications in plasma fibrinogen. DESIGN: Descriptive, prospective pharmacological intervention study, with two transversal cuts, one at the start and one after 6 months pravastatin treatment. SETTING: Health area located in the suburbs of Valencia. PATIENTS: Hypercholesterolaemia cases diagnosed de novo and treated with pravastatin for 6 months. Sample size was calculated for paired data with an alpha error of 0.05 and a beta error of 20%. The fibrinogen difference thought relevant was set at 40 mg/dl. Variability was deduced from a mini-sample of 15 cases, obtaining a total of 57 patients. Sex, age, height, weight, BMI, count, formula, globular sedimentation rate (GSR), glucaemia, total, HDL and LDL cholesterol, and triglycerides were recorded. MEASUREMENTS AND MAIN RESULTS: Mean age was 55.9, height 161.9 cm and initial weight 73.9 kg (mean BMI 28.1 kg/m(2)). After six months pravastatin treatment (10/20 mg/day) we found no significant differences in glucaemia, GSR or leukocytes. There were differences in weight, that fell by 1.5 kg (0.6 kg/m(2)), systolic pressure (4.3 mmHg) and diastolic pressure (2.7 mmHg) on average. We found the following differences for lipids: 42.3 mg/dl (15.2%) drop in mean total cholesterol, 27 mg/dl (14.5%) in LDL cholesterol, and 36.2 mg/dl (21.9%) in triglycerides. We found a mean increase in HDL cholesterol of 4.4 mg/dl. There was a mean drop of 43.7 mg/dl (11.9%) in fibrinogen. CONCLUSIONS: We found an 11.9% drop of plasma fibrinogen in patients with hypercholesterolaemia treated with pravastatin.
Authors: G Dangas; D A Smith; J J Badimon; A H Unger; J H Shao; P Meraj; A M Cohen; D Levine; J T Fallon; J A Ambrose Journal: Am J Cardiol Date: 1999-09-15 Impact factor: 2.778
Authors: G Dangas; J J Badimon; D A Smith; A H Unger; D Levine; J H Shao; P Meraj; C Fier; J T Fallon; J A Ambrose Journal: J Am Coll Cardiol Date: 1999-04 Impact factor: 24.094
Authors: A R Folsom; K K Wu; M Rasmussen; L E Chambless; N Aleksic; F J Nieto Journal: Arterioscler Thromb Vasc Biol Date: 2000-02 Impact factor: 8.311
Authors: H Wada; Y Mori; T Kaneko; Y Wakita; K Minamikawa; M Ohiwa; S Tamaki; N Yokoyama; T Kobayashi; K Deguchi Journal: Clin Ther Date: 1992 Nov-Dec Impact factor: 3.393